Clinical Trials Browser

Head and Neck Neoplasms × bivatuzumab mertansine × Clear all

NCT02254018 2023-10-24

Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck

Phase 1 Completed

Head and Neck Neoplasms